Financial Analysis: SWEDISH ORPHAN/S (OTCMKTS:SWTUY) vs. Carrefour (OTCMKTS:CRRFY)

SWEDISH ORPHAN/S (OTCMKTS:SWTUY) and Carrefour (OTCMKTS:CRRFY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.

Earnings & Valuation

This table compares SWEDISH ORPHAN/S and Carrefour”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SWEDISH ORPHAN/S	$763.19 million	8.71	$134.73 million	$0.50	48.76
Carrefour	$91.89 billion	0.11	$1.80 billion	N/A	N/A

Carrefour has higher revenue and earnings than SWEDISH ORPHAN/S.

Risk & Volatility

SWEDISH ORPHAN/S has a beta of 1.81, suggesting that its share price is 81% more volatile than the S&P 500. Comparatively, Carrefour has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for SWEDISH ORPHAN/S and Carrefour, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SWEDISH ORPHAN/S	0	0	0	0	0.00
Carrefour	0	1	0	0	2.00

Profitability

This table compares SWEDISH ORPHAN/S and Carrefour’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
SWEDISH ORPHAN/S	25.75%	29.63%	18.74%
Carrefour	N/A	N/A	N/A

Institutional & Insider Ownership

0.1% of Carrefour shares are owned by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

SWEDISH ORPHAN/S beats Carrefour on 5 of the 9 factors compared between the two stocks.

About SWEDISH ORPHAN/S

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetic and lysosomal diseases. The company offers Elocta to treat haemophilia A; and Alprolix to treat haemophilia B. It also provides Orfadin for the treatment of hereditary tyrosinaemia type 1; and Kineret for the treatment of auto inflammatory condition, as well as Xiapex to treat Dupuytren's contracture and Peyronie's disease. In addition, the company manufactures drug substance for ReFacto AF; and develops BIVV001 and BIVV002 for the treatment of hemophilia. It operates in Sweden, the Middle East, North Africa, Russia, North America, other European countries, and internationally. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix, as well as XTEN-programs. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.

About Carrefour

Carrefour SA engages in the operation of stores that offer food and non-food products in various formats and channels in France, Spain, Italy, Belgium, Poland, Romania, Brazil, and Argentina, as well as in the Middle East, Africa, and Asia. The company operates hypermarkets, supermarkets, convenience stores, club stores, and cash and carry stores; e-commerce sites; and service stations. It is also involved in banking, insurance, property development, and franchise activities; the provision of travel agency services; and the rental of shopping malls. The company was founded in 1959 and is based in Massy, France.